// App-Quantinova.ai

4519 : Gut microbiome composition to predict resistance in renal cell carcinoma (RCC) patients on nivolumab.

Researchers

Presenter

  • Lisa Derosa

Principal Investigators

  • Valerio Iebba

  • Laurence Albiges

  • Marine Fidelle

  • Melodie Bonvalet

  • Emeline Colomba

  • Laurence Zitvogel

  • Bernard Escudier

  • Bertrand Routy

Medical Centers

  • U1015 INSERM, Gustave Roussy Cancer Campus, Paris Saclay University, Villejuif, France

  • Gustave Roussy Cancer Campus, Villejuif, France

  • Medical Oncology, Gustave Roussy, Universite Paris-Saclay, Villejuif, France, Villejuif, France

  • Gustave Roussy Cancer Campus and Paris-Sud University, Villejuif, France

  • Centre de recherche du Centre hospitalier de lUniversite de Montreal (CRCHUM), Montreal, Qc, Canada, Montreal, QC, Canada

Locations

  • France

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • N/A

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved